A major new study has pinpointed five specific compounds in the blood that appear to protect against high myopia, a severe form of nearsightedness that can lead to permanent vision loss. Scientists used genetic data from over 50,000 people to identify these metabolites as potential biomarkers and drug targets, opening a path toward early intervention before serious eye damage occurs.

What Is High Myopia and Why Does It Matter?

High myopia is more than just needing strong glasses. It's a progressive eye condition where the eyeball becomes abnormally elongated, stretching the retina and other delicate eye structures. Over time, this can trigger pathological changes that lead to irreversible vision loss, including complications like retinal detachment, glaucoma, and macular degeneration. Because high myopia increases the risk of these serious conditions, identifying ways to prevent or slow its progression is critical for eye health.

Which Blood Markers Show the Most Promise?

Researchers conducted a systematic analysis of 122 blood metabolites, which are chemical compounds produced during metabolism, using genetic data from three large genome-wide association studies (GWASs). They then cross-referenced this data with information on high myopia from a study of 50,372 participants in the UK Biobank. The analysis identified five metabolites as both biomarkers and potential drug targets.

The five key metabolites are:

• Glutamine: An amino acid that showed a 24% reduction in high myopia risk in real-world case-control studies, with strong statistical certainty.
• Tyrosine: Another amino acid that demonstrated a 28% reduction in high myopia risk when levels were higher, based on case-control validation.
• Degree of unsaturation: A measure related to fat composition in the blood that showed protective effects against high myopia development.
• Docosahexaenoic acid (DHA): An omega-3 fatty acid commonly found in fish and seafood, which appeared to lower myopia risk.
• Isobutyrylcarnitine: A compound involved in energy metabolism that showed increased risk when elevated, suggesting it may work differently than the others.

The case-control study, which compared people with high myopia to those without it, confirmed that glutamine and tyrosine levels were significantly associated with lower myopia risk. Glutamine showed odds of 0.76, meaning higher levels were linked to substantially lower risk, while tyrosine showed odds of 0.72.

How Could This Lead to New Treatments?

The identification of these metabolites as causal factors, rather than just markers, is significant because it suggests they could become targets for drug development. If researchers can develop medications or interventions that raise levels of protective metabolites like glutamine, tyrosine, and DHA, or lower levels of isobutyrylcarnitine, they may be able to slow or prevent high myopia progression in people at risk.

This approach differs from current myopia management strategies. While existing treatments like low-dose atropine eye drops and red-light therapy can slow myopia progression in children, they don't address the underlying metabolic factors that may drive the condition. A metabolite-based approach could offer a more targeted intervention earlier in the disease process.

What Are the Next Steps for Researchers?

While the findings are promising, researchers emphasized that further investigation is needed. The study authors noted that validation of the therapeutic efficacy and clarification of the underlying biological mechanisms are essential before these metabolites can be translated into clinical treatments. This means laboratory studies and clinical trials will be necessary to confirm that modifying these metabolites actually prevents or slows myopia in real patients.

The research represents a shift toward precision medicine in ophthalmology, where treatments are tailored to individual metabolic profiles rather than applying a one-size-fits-all approach. For people with a family history of high myopia or those already showing signs of myopia progression, this metabolite-based approach could eventually offer a preventive option.

How to Protect Your Vision While Research Continues

• Schedule regular eye exams: Early detection of myopia progression allows for timely intervention with proven strategies like atropine drops or red-light therapy.
• Increase outdoor time: Studies show that spending more time outdoors, particularly in natural light, is associated with slower myopia progression in children and adolescents.
• Monitor dietary sources of omega-3s: Since DHA, an omega-3 fatty acid, emerged as a protective metabolite, consuming fish and other omega-3-rich foods may support eye health, though more research is needed to confirm direct benefits.
• Discuss metabolic screening with your eye doctor: As this research advances, ask your ophthalmologist whether blood metabolite testing might be appropriate for your individual risk profile.

The discovery of these five blood metabolites marks an important step toward understanding the metabolic roots of high myopia. While it will take time to develop and test new treatments based on these findings, the research offers hope that future patients may have access to more precise, preventive interventions that address the biological mechanisms driving this sight-threatening condition.